# MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients

> **NCT02213744** · PHASE2,PHASE3 · TERMINATED · sponsor: **Merrimack Pharmaceuticals** · enrollment: 113 (actual)

## Conditions studied

- Breast Cancer
- HER2 Positive Breast Cancer

## Interventions

- **DRUG:** MM-302
- **DRUG:** Gemcitabine
- **DRUG:** Capecitabine
- **DRUG:** Vinorelbine
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT02213744
- **Lead sponsor:** Merrimack Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07
- **Primary completion:** 2016-12
- **Final completion:** 2017-06
- **Target enrollment:** 113 (ACTUAL)
- **Why stopped:** Felt not to show benefit over control per DMC and confirmed via futility analysis
- **Last updated:** 2017-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02213744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02213744, "MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02213744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*